Shots:  

• Pfizer to sponsor & conduct P-Ib/II study evaluating the safety- tolerability- and preliminary efficacy of dual regimen and will assume costs of study & other expenses related to IP rights.  The companies will form a joint development committee to manage clinical study which is anticipated to commence in H1’21
• The focus of the collaboration is to evaluate SpringWorks’ Nirogacestat + Pfizer’s PF‐06863135- in patients with r/r MM. Additionally- SpringWorks is currently conducting a global P-III DeFi trial to evaluate nirogacestat in adults with progressing desmoid tumors
• Nirogacestat is investigational- oral- selective- small-molecule GSI in P-III while PF‐06863135 is anti-BCMA CD3 bispecific Ab (SC)- being investigated in P-I study to treat r/r MM

­ Ref: PRNewswire | Image: Solar Winds MSP